185 related articles for article (PubMed ID: 3707598)
1. Inhibition of liver glutathione S-transferase activity in rats by hypolipidemic drugs related or unrelated to clofibrate.
Foliot A; Touchard D; Mallet L
Biochem Pharmacol; 1986 May; 35(10):1685-90. PubMed ID: 3707598
[TBL] [Abstract][Full Text] [Related]
2. Impairment of hepatic glutathione S-transferase activity as a cause of reduced biliary sulfobromophthalein excretion in clofibrate-treated rats.
Foliot A; Touchard D; Celier C
Biochem Pharmacol; 1984 Sep; 33(18):2829-34. PubMed ID: 6477642
[TBL] [Abstract][Full Text] [Related]
3. Irreversible inhibition of hepatic glutathione S-transferase by ciprofibrate, a peroxisome proliferator.
Awasthi YC; Singh SV; Goel SK; Reddy JK
Biochem Biophys Res Commun; 1984 Sep; 123(3):1012-8. PubMed ID: 6487318
[TBL] [Abstract][Full Text] [Related]
4. Impairment of sulfobromophthalein biliary excretion and inhibition of glutathione S-transferase activity induced by perhexiline maleate in rats.
Mariscal MA; Muñoz ME; Collado PS; Esteller A; Gonzalez J
Biochem Pharmacol; 1988 Sep; 37(18):3461-5. PubMed ID: 3421996
[TBL] [Abstract][Full Text] [Related]
5. The hepatocellular transport of sulfobromophthalein-glutathione by clofibrate treated, perfused rat liver.
Sorrentino D; Weisiger RA; Bass NM; Licko V
Lipids; 1989 May; 24(5):438-42. PubMed ID: 2755320
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mitochondrial respiration and oxygen-dependent hepatotoxicity by six structurally dissimilar peroxisomal proliferating agents.
Keller BJ; Yamanaka H; Thurman RG
Toxicology; 1992; 71(1-2):49-61. PubMed ID: 1729767
[TBL] [Abstract][Full Text] [Related]
7. Effects of clofibric and beclobric acid in rat and monkey hepatocyte primary culture: influence on peroxisomal and mitochondrial beta-oxidation and the activity of catalase, glutathione S-transferase and glutathione peroxidase.
Mennes WC; Wortelboer HM; Hassing GA; van Sandwijk K; Timmerman A; Schmid BP; Jahn U; Blaauboer BJ
Arch Toxicol; 1994; 68(8):506-11. PubMed ID: 7802591
[TBL] [Abstract][Full Text] [Related]
8. Effect of peroxisome proliferators on glutathione-dependent sulphobromophthalein excretion.
James SI; Ahokas JT
Xenobiotica; 1992 Dec; 22(12):1425-32. PubMed ID: 1494887
[TBL] [Abstract][Full Text] [Related]
9. Species differences in the hepatic response to a potent peroxisome proliferator.
Makowska JM; Bonner FW; Goldfarb PS; Gibson GG
Biochem Soc Trans; 1989 Dec; 17(6):1072-3. PubMed ID: 2628085
[No Abstract] [Full Text] [Related]
10. Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strain. Co-induction of microsomal cytochrome P-450 IVA1 and peroxisome proliferation.
Makowska JM; Anders C; Goldfarb PS; Bonner F; Gibson GG
Biochem Pharmacol; 1990 Sep; 40(5):1083-93. PubMed ID: 2390105
[TBL] [Abstract][Full Text] [Related]
11. The effect of three hypolipidemic drugs on catalase activity and peroxisomal and mitochondrial palmitate oxidation in rat cardiac and skeletal muscle.
MacDonald RS; Swan PB
Biochim Biophys Acta; 1986 Feb; 880(2-3):153-60. PubMed ID: 3942787
[TBL] [Abstract][Full Text] [Related]
12. Effects of joint exposures to selected peroxisome proliferators on hepatic acyl-CoA oxidase activity in male B6C3F1 mice.
Ochs JB; Baldwin LA; Leonard DA; Calabrese EJ
Hum Exp Toxicol; 1992 Mar; 11(2):83-8. PubMed ID: 1349224
[TBL] [Abstract][Full Text] [Related]
13. Effect of hypolipidemic compounds on lauric acid hydroxylation and phase II enzymes.
Thomas H; Schladt L; Knehr M; Post K; Oesch F; Boiteux-Antoine AF; Fournel-Gigleux S; Magdalou J; Siest G
Biochem Pharmacol; 1989 Jun; 38(12):1963-9. PubMed ID: 2500933
[TBL] [Abstract][Full Text] [Related]
14. Specificity in the action of hypolipidemic drugs: increase of peroxisomal beta-oxidation largely dissociated from hepatomegaly and peroxisome proliferation in the rat.
Lazarow PB; Shio H; Leroy-Houyet MA
J Lipid Res; 1982 Feb; 23(2):317-26. PubMed ID: 7077146
[TBL] [Abstract][Full Text] [Related]
15. Expression of liver peroxisomal proteins as compared to other organelle marker enzymes in rats treated with hypolipidemic agents.
Cherkaoui Malki M; Bardot O; Lhuguenot JC; Latruffe N
Biol Cell; 1990; 69(2):83-92. PubMed ID: 2271901
[TBL] [Abstract][Full Text] [Related]
16. 32P-postlabeling analysis of peroxisome proliferator-DNA adduct formation in rat liver in vivo and hepatocytes in vitro.
Gupta RC; Goel SK; Earley K; Singh B; Reddy JK
Carcinogenesis; 1985 Jun; 6(6):933-6. PubMed ID: 4006083
[TBL] [Abstract][Full Text] [Related]
17. Differential proto-oncogene mRNA induction from rats treated with peroxisome proliferators.
Cherkaoui Malki M; Lone YC; Corral-Debrinski M; Latruffe N
Biochem Biophys Res Commun; 1990 Dec; 173(3):855-61. PubMed ID: 2268348
[TBL] [Abstract][Full Text] [Related]
18. The effect of beclobric acid and clofibric acid on peroxisomal beta-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes.
Blaauboer BJ; van Holsteijn CW; Bleumink R; Mennes WC; van Pelt FN; Yap SH; van Pelt JF; van Iersel AA; Timmerman A; Schmid BP
Biochem Pharmacol; 1990 Aug; 40(3):521-8. PubMed ID: 2383284
[TBL] [Abstract][Full Text] [Related]
19. Alteration of rat liver endoplasmic reticulum Ca(2+)-ATPase thiol integrity by ciprofibrate, a peroxisome proliferator.
Bennett AM; Williams GM
Biochem Pharmacol; 1993 May; 45(10):2093-8. PubMed ID: 8512590
[TBL] [Abstract][Full Text] [Related]
20. Effects of some hypolipidemic agents on biochemical values and hepatic peroxisomal enzymes in rats: comparison of probucol, CGA, KCD-232, MLM-160, AL-369 and clinofibrate with clofibrate.
Watanabe T; Mitsukawa M; Horie S; Suga T; Seki K
J Pharmacobiodyn; 1987 Mar; 10(3):142-7. PubMed ID: 3625448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
